Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The uptake of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the US for weight loss has been profound. However, compounded GLP-1's, generic versions of the drugs, have upended pricing models for market leader Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide).

Our cover feature examines the effect the FDA's order that compounders stop producing versions of semaglutide and tirzepatide as both drugs are no longer in short supply is liable to have on the market.

Also in this issue, we look at whether pharma tariffs can ''Make America Manufacture Again' and how companies are navigating the psychedelic drug-trial  field. And don’t miss our roundup of the biggest news from this year's American Society of Clinical Oncology meeting.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor